JAB-3312
- Generic Name
- JAB-3312
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Conditions
- Non-small Cell Lung CancerKRAS P.G12CColorectal CancerPancreatic Ductal Carcinoma
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05288205
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
- Conditions
- Solid TumorNSCLC
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04720976
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
- Conditions
- Colorectal CancerNon-small Cell Lung CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaBreast CancerOther Solid TumorsPancreatic Ductal Carcinoma
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04121286
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical Collage Hospital, Beijing, China
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
- Conditions
- Colorectal CancerPancreatic Ductal CarcinomaEsophageal Squamous Cell CarcinomaBreast CancerNon-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaOther Solid Tumors
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04045496
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸HealthONE Clinic Services Oncology-Hematology, Denver, Colorado, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.